1. Home
  2. ADTX vs GRI Comparison

ADTX vs GRI Comparison

Compare ADTX & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aditxt Inc.

ADTX

Aditxt Inc.

HOLD

Current Price

$1.11

Market Cap

2.0M

Sector

Health Care

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$0.29

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADTX
GRI
Founded
2017
2018
Country
United States
United States
Employees
26
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
1.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ADTX
GRI
Price
$1.11
$0.29
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.00
AVG Volume (30 Days)
4.2M
1.5M
Earning Date
11-18-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,945.00
N/A
Revenue This Year
$15,768.94
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$0.27
52 Week High
$6,412.72
$15.64

Technical Indicators

Market Signals
Indicator
ADTX
GRI
Relative Strength Index (RSI) 36.31 19.52
Support Level $1.30 $0.33
Resistance Level $1.33 $2.17
Average True Range (ATR) 0.44 0.12
MACD -0.13 -0.06
Stochastic Oscillator 2.22 0.60

Price Performance

Historical Comparison
ADTX
GRI

About ADTX Aditxt Inc.

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: